Risk factors for ribavirin treatment failure in Asian organ transplant recipients with chronic hepatitis E infection

Table 1 Demographics and clinical characteristics of 10 patients

Variables	Value
Age, yr
Mean	47
Range	34-59
Male gender, n (%)	8 (80)
Type of organ transplant, n (%)
Liver	4 (40)
Kidney	5 (50)
Bone Marrow	1 (10)
Time from transplant to unexplained transaminitis in mo
Median	41.5
Range	0.5-276
Time from transplant to diagnosis of HEV in mo
Median	43.0
Range	0.5-276
Immunosuppressive therapy at the diagnosis of HEV, n (%)
Tacrolimus	6 (60)
Cyclosporin	1 (10)
Mycophenolate	6 (60)
Azathioprine	3 (30)
Prednisolone	7 (70)
Sirolimus	1 (10)
BEAM-R	1 (10)
(carmustine, etoposide, cytarabine, and melphalan – rituximab)
Peak alanine transaminase, as U/L
Median	213
Range	133-8127
Peak aspartate aminotransferase, as U/L
Median	203
Range	84-2591
Baseline estimated glomerular filtration rate, as mL/min
Median	63
Range	27-108
Baseline creatinine, as μmol/L
Median	141
Range	66-323

HEV: Hepatitis E virus.